Crossmark

Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors

Crossref DOI link: https://doi.org/10.1007/s40266-019-00644-1

Published Online: 2019-02-20

Published Print: 2019-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Esther, John

Hale, Peter

Hahn, Andrew W.

Agarwal, Neeraj

Maughan, Benjamin L.
License Information

Text and Data Mining valid from 2019-02-20
More Information

Article History

First Online: 20 February 2019

Compliance with Ethical Standards

:

: No external funding was used in the preparation of this manuscript.

: John Esther, Peter Hale, and Andrew W. Hahn declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Neeraj Agarwal reports consultancy to the following: Pfizer, Novartis, Merck, Genentech, Eisai, Exelixis, Clovis, EMD Serono, BMS, Astra Zeneca, Foundation One, Astellas, Ely Lilly, Bayer, Argos, Medivation, Clovis, and Nektar. Neeraj Agarwal also reports research funding to his institution on his behalf from the following companies: Active Biotech, Astra Zeneca, Bavarian Nordic, BMS, Calithera, Celldex, Eisai, Exelixis, Genetech, GSK (glaxosmithkline), Immunomedics, Janssen, Medivation, Merck, New link Genetics, Novartis, Pfizer, Prometheus, Rexahn, Sanofi, Takeda, and Tracon. Benjamin L. Maughan reports consultancy to the following companies: Tempus, Exelixis, Peloton, and Janssen Oncology.